Danielle Rice, MD
Neurology · Park Ridge, ILNPI 1184942013
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.9%), consulting fees and education — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Biogen at 46.1% of the total. Reporting peaked in 2023 at $411 and has fallen 93.0% since, to $29 in 2024.
Across 11 payments — averaging $90.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$459
- Novartis$225
- Sanofi$154
- AstraZeneca$91
- AbbVie$66
Across 4 payments — averaging $8036.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$32K
What the payments were for
- Consulting fees$45045%
- Food & beverage$53654%
- Education$91%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 4 | $459 |
| Novartis | 1 | $225 |
| Sanofi | 2 | $154 |
| AstraZeneca | 1 | $91 |
| AbbVie(2 entities) | 3 | $66 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$450
How this compares
$995 in reported general payments places this provider in the 55th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZeposiaOzanimod Hydrochloride | 12 | $101,479 |
| Plegridy PenPeginterferon Beta-1a | 11 | $90,924 |
| Dalfampridine ErDalfampridine | 16 | $23,995 |
| Gabapentin | 59 | $1,360 |
| Modafinil | 18 | $1,239 |
| Baclofen | 29 | $879 |
| Levetiracetam | 16 | $546 |
| Pregabalin | 16 | $526 |
| Propranolol Hcl | 17 | $248 |
| Topiramate | 25 | $248 |
| Amitriptyline Hcl | 19 | $228 |
| Lamotrigine | 19 | $142 |
| RizatriptanRizatriptan Benzoate | 11 | $128 |
Paid to pharmacies, not to this prescriber.
Other neurology in Park Ridge
- Michael RezakPark Ridge$184K
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.